Eton Pharmaceuticals
About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc., a privately held company, is focused on the development and commercialization of innovative sterile injectable product candidates utilizing the FDA 505(b)(2) regulatory pathway.109 articles about Eton Pharmaceuticals
-
Eton Pharmaceuticals Submits New Drug Application to the FDA for Zonisamide Oral Suspension (ET-104)
7/30/2020
- Application Submitted for the Treatment of Partial Seizures in Epilepsy Patients - Eton’s Patent-Pending Product Addresses Significant Unmet Need for a Liquid Formulation of Zonisamide - Application is Eton’s Sixth Drug Application Under FDA Review
-
Eton Pharmaceuticals Submits New Drug Application to the FDA for Orphan Drug Dehydrated Alcohol Injection (DS-100)
7/27/2020
-Granted Orphan Drug Designation by the FDA for the Treatment of Methanol Poisoning -Since the Start of COVID-19, the FDA has Recalled More Than 75 Contaminated Hand Sanitizers Due to Risk of Methanol Poisoning -DS-100 is Eton’s Fifth Drug Application Under FDA Review and Second Orphan Application DEER PARK, Ill., July 27, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products
-
Eton Pharmaceuticals Announces First Quarter 2020 Financial Results
5/14/2020
Eton Pharmaceuticals, Inc, a specialty pharmaceutical company focused on developing and commercializing innovative drug products, reported financial results for the first quarter ended March 31, 2020 and provided an update on business progress.
-
Eton Pharmaceuticals Confirms First-to-File Patent Challenge on Elcys (Cysteine Hydrochloride Injection)
5/7/2020
-Eton confirms first-to-file ANDA referencing Exela Pharma Sciences’ Elcys product -Eton plans to file Post Grant Reviews in the U.S. Patent & Trademark Office challenging the validity of Exela’s listed patents, which, if successful, could allow Eton to launch in 2021 -Eton believes Exela Pharma Sciences is improperly stifling competition on a decades-old drug
-
Eton Pharmaceuticals to Report First Quarter Financial Results on Thursday, May 14, 2020
5/6/2020
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report first quarter 2020 financial and operating results on Thursday, May 14, 2020
-
Eton Pharmaceuticals Announces Appointment of Paul Stickler as Senior Vice President of Sales and MarketingOrphan Drug Expert Paul Stickler to Lead Eton’s Commercialization of Alkindi® Sprinkle and Pediatric Neurology Franchise
5/4/2020
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it has appointed Paul Stickler as the company’s new Senior Vice President of Sales and Marketing. Stickler brings more than twenty-five years of pharmaceutical sales and marketing experience with a primary focus in orphan and neurology products. In the new role, he will be responsi
-
Eton Pharmaceuticals Announces Acquisition of U.S Marketing Rights to Pediatric Orphan Drug Alkindi® Sprinkle
3/27/2020
-Estimated Market Opportunity of Greater than $100 Million -Alkindi Sprinkle NDA has been Assigned a September 29, 2020 Prescription Drug User Fee Act Date -Alkindi Sprinkle has been Granted Orphan Drug Designation for Adrenal Insufficiency in Pediatric Patients -Eton Executed $7.8 Million Equity Financing and $2.0 Million Amended Credit Facility to Support Alkindi Sprinkle Transaction
-
Eton Pharmaceuticals Reports Positive Study Results for ET-101 (Topiramate Oral Solution)
3/17/2020
Eton Pharmaceuticals, Inc today announced positive bioequivalence study results for ET-101, its proprietary oral solution formulation of topiramate. A bioequivalen
-
The U.S. Food and Drug Administration has two PDUFA dates this week, one for a type of epilepsy and the other for a triple-combination drug for cystic fibrosis. Here’s a look.
-
Eton Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Financial Results
3/5/2020
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today reported financial results for the fourth quarter ended December 31, 2019 and provided an update on business progress.
-
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, March 5, 2020
2/27/2020
Eton Pharmaceuticals, Inc, a specialty pharmaceutical company focused on developing and commercializing innovative drug products, announced that it will report fourth quarter and full year 2019 financial and operating results on Thursday, March 5, 2020.
-
Eton Pharmaceuticals Provides Update on ET-105 Program
2/19/2020
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today provided an update on its ET-105 product candidate, which is currently under review with the U.S. Food and Drug Administration (FDA).
-
Eton Pharmaceuticals to Present at the 9th Annual SVB Leerink Healthcare Conference
2/13/2020
Eton Pharmaceuticals, Inc. announced that Sean Brynjelsen, Chief Executive Officer, will present at the 9th Annual SVB Leerink Healthcare Conference on Tuesday, February 25, 2020 in New York, NY.
-
Eton Pharmaceuticals and Xellia Pharmaceuticals Announce Biorphen® (phenylephrine HCl) Co-Promotion Agreement
1/21/2020
Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, announced it has entered into a co-promotion agreement with Xellia Pharmaceuticals for the promotion of Biorphen® (phenylephrine HCl), the first and only FDA approved ready-to-use formulation of phenylephrine injection indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.
-
Eton Pharmaceuticals Announces Commercial Availability of Biorphen® (phenylephrine HCI) Injection
12/2/2019
Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that Biorphen®, the first and only FDA-approved ready-to-use formulation of phenylephrine for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia, is now commercially available
-
Eton Pharmaceuticals Announces Third Quarter Financial Results and Highlights Business Progress
11/14/2019
Eton Pharmaceuticals, Inc reported financial results for the third quarter ended September 30, 2019 and provided an update on business progress.
-
Eton Pharmaceuticals Announces $10 Million Debt Facility with SWK Holdings
11/13/2019
Eton Pharmaceuticals, Inc announced it has entered into a $10 million debt facility with SWK Holdings Corporation.
-
Eton Pharmaceuticals to Report Third Quarter 2019 Financial Results on Thursday, November 14, 2019
11/6/2019
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report third quarter 2019 financial and operating results on Thursday, November 14, 2019.
-
Eton Pharmaceuticals Announces U.S. FDA Approval of Biorphen® (phenylephrine HCI) Injection
10/22/2019
Eton Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved Biorphen®, the first and only FDA-approved ready-to-use formulation of phenylephrine for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.
-
We round out the month of October and start the month of November with four PDUFA dates on the U.S. Food and Drug Administration’s calendar. Here’s a look.